Novel Targets, Novel Agents: How Our Newest Biologics Fit Into the Psoriatic Arthritis Treatment Paradigm
Cathy Patty-Resk, MSN, RN-BC, CPNP-PC
Pediatric Nurse Practitioner
Children’s Hospital of Michigan
This activity has been designed to meet the educational needs of rheumatology nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.
Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:
- Assess the current use of FDA-approved biologic agents for the treatment of psoriatic arthritis in your practice
- Identify opportunities to better educate patients about drug efficacy and safety to improve overall adherence
The Rheumatology Nurses Society is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500).
Rheumatology Nurses Society designates this educational activity for 0.25 contact hours (0.25 pharmacotherapeutic contact hours).
According to the disclosure policy of RNS, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.
Relationships are abbreviated as follows: E, Educational planning committee; G, Grant/research support recipient; A, Advisor/review panel member; C, Consultant; S, Stock shareholder; SB, Speaker bureau; PE, Promotional event talks; H, Honoraria; O, Other.
Disclosures are as follows:
Cathy Patty-Resk, MSN, RN-BC, CPNP-PC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Novartis, Sandoz/AB.
Kim Cheramie, MSN, RN-BC, Lead Nurse Planner, Rheumatology Nurses Society, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.
Scott Kober, MBA, President, MedCaseWriter, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.
Kevin Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.
Off-Label Product Disclosure
This activity will include a discussion of off-label or investigational use of the following: Risankizumab, bimenkizumab, LAS41008 (dimethyl fumerate), and piclidenoson (CF101).
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE contact hours for your participation, please complete the post-test (achieving a passing grade of 75% or greater), and program evaluation. Your certificate can be printed immediately.
This activity is supported by educational grants from Lilly and Celgene.